Department of Chemical Sciences, University of Padova, Padova, Italy.
Anticancer Agents Med Chem. 2010 May;10(4):283-92. doi: 10.2174/187152010791162298.
In this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer drug cisplatin. Starting from the rationale behind our investigations, we here summarize the results achieved so far, focusing on the latest in-depth mechanistic studies that have recently provided insights into their mechanism of action, thus opening up new prospects for further pharmacological testing and, hopefully, to enter clinical trials.
在这篇综述论文中，我们旨在详细介绍我们致力于设计基于金的抗癌剂的研究工作。特别是，在过去十年中，我们一直在开发一些金（III）-二硫代氨基甲酸盐衍生物，与参考临床抗癌药物顺铂相比，它们具有出色的体外和体内抗肿瘤特性，并且系统和肾脏毒性降低，甚至没有。从我们研究背后的基本原理出发，我们在这里总结迄今为止取得的结果，重点介绍最近深入的机制研究，这些研究最近提供了对其作用机制的深入了解，从而为进一步的药理学测试开辟了新的前景，并希望进入临床试验。
